Get the Stockscreener App
3.03
1.34%
0.04
Pre-market:
2.96
-0.07
-2.31%
Grace Therapeutics Inc stock is traded at $3.03, with a volume of 61,800.
It is up +1.34% in the last 24 hours and up +1.68% over the past month.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
See More
Previous Close:
$2.99
Open:
$2.95
24h Volume:
61,800
Relative Volume:
0.89
Market Cap:
$41.90M
Revenue:
-
Net Income/Loss:
$-10.31M
P/E Ratio:
-3.9351
EPS:
-0.77
Net Cash Flow:
$-12.65M
1W Performance:
-6.77%
1M Performance:
+1.68%
6M Performance:
+0.33%
1Y Performance:
+0.00%
1-Day Range:
$2.91
$3.06
1-Week Range:
$2.91
$3.39
52-Week Range:
$1.75
$4.965
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
3.03 | 41.35M | 0 | -10.31M | -12.65M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | TD Cowen | Buy |
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
How to manage a losing position in Grace Therapeutics Inc.July 2025 Volume & Low Drawdown Investment Ideas - Newser
Advanced analytics toolkit walkthrough for Grace Therapeutics Inc.2025 Investor Takeaways & Technical Buy Zone Confirmation - Newser
Can trapped investors hope for a rebound in Grace Therapeutics Inc.Weekly Risk Report & AI Powered Trade Plan Recommendations - Newser
How hedge fund analytics apply to Grace Therapeutics Inc. stockWeekly Trade Review & High Win Rate Trade Alerts - Newser
Volume Surge May Signal Institutional Interest in Grace Therapeutics Inc. getLinesFromResByArray error: size == 0 - thegnnews.com
Will Grace Therapeutics Inc. see short term momentumTrade Performance Summary & Weekly Watchlist of Top Performers - Newser
Evaluating Grace Therapeutics Inc. with trendline analysisQuarterly Earnings Summary & Weekly Watchlist for Hot Stocks - Newser
Is it time to cut losses on Grace Therapeutics Inc.Trade Risk Summary & Comprehensive Market Scan Insights - Newser
Short interest data insights for Grace Therapeutics Inc.2025 AllTime Highs & Verified Short-Term Plans - Newser
Grace Therapeutics Inc. stock trend outlook and recovery pathWeekly Earnings Recap & Safe Entry Momentum Tips - Newser
Grace Therapeutics Inc. stock daily chart insights2025 Analyst Calls & Daily Profit Maximizing Trade Tips - Newser
Pattern recognition hints at Grace Therapeutics Inc. upsideWeekly Loss Report & AI Driven Price Predictions - Newser
Ranking Grace Therapeutics Inc. among high performing stocks via toolsWall Street Watch & Weekly Top Gainers Trade List - Newser
Sector ETF Data Correlates with Strength in Grace Therapeutics Inc. getLinesFromResByArray error: size == 0 - thegnnews.com
Exit strategy if you’re trapped in Grace Therapeutics Inc.Quarterly Market Summary & Precise Trade Entry Recommendations - Newser
Visual trend scoring systems applied to Grace Therapeutics Inc.Buy Signal & Risk Controlled Stock Alerts - Newser
Is Grace Therapeutics Inc. forming bullish engulfing patterns getLinesFromResByArray error: size == 0 - sisain.net
Grace Therapeutics Inc. recovery potential after sell offMarket Performance Recap & Weekly Stock Performance Updates - Newser
How to forecast Grace Therapeutics Inc. trends using time seriesTrade Performance Summary & High Win Rate Trade Alerts - Newser
Using Bollinger Bands to evaluate Grace Therapeutics Inc.July 2025 WrapUp & Real-Time Market Sentiment Reports - Newser
Multi asset correlation models including Grace Therapeutics Inc.2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - Newser
RSI + MACD Show Convergence for Grace Therapeutics Inc. getLinesFromResByArray error: size == 0 - thegnnews.com
When is the best time to exit Grace Therapeutics Inc.Market Activity Summary & Free Daily Entry Point Trade Alerts - Newser
Applying Elliott Wave Theory to Grace Therapeutics Inc.Trade Analysis Report & Growth Oriented Trade Recommendations - Newser
How Grace Therapeutics Inc. stock performs during market volatilityWall Street Watch & Long-Term Investment Growth Plans - Newser
Key resistance and support levels for Grace Therapeutics Inc.2025 Year in Review & Free Expert Verified Stock Movement Alerts - Newser
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):